Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 286

1.

Frequency and longitudinal clinical outcomes of Alzheimer's AT(N) biomarker profiles: A longitudinal study.

Yu JT, Li JQ, Suckling J, Feng L, Pan A, Wang YJ, Song B, Zhu SL, Li DH, Wang HF, Tan CC, Dong Q, Tan L, Mok V, Aisen PS, Weiner MM; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2019 Aug 6. pii: S1552-5260(19)30147-5. doi: 10.1016/j.jalz.2019.05.006. [Epub ahead of print]

PMID:
31399333
2.

Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease.

Egan MF, Mukai Y, Voss T, Kost J, Stone J, Furtek C, Mahoney E, Cummings JL, Tariot PN, Aisen PS, Vellas B, Lines C, Michelson D.

Alzheimers Res Ther. 2019 Aug 7;11(1):68. doi: 10.1186/s13195-019-0520-1.

3.

The relative efficiency of time-to-progression and continuous measures of cognition in presymptomatic Alzheimer's disease.

Li D, Iddi S, Aisen PS, Thompson WK, Donohue MC.

Alzheimers Dement (N Y). 2019 Jul 18;5:308-318. doi: 10.1016/j.trci.2019.04.004. eCollection 2019.

4.

Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial.

van Dyck CH, Nygaard HB, Chen K, Donohue MC, Raman R, Rissman RA, Brewer JB, Koeppe RA, Chow TW, Rafii MS, Gessert D, Choi J, Turner RS, Kaye JA, Gale SA, Reiman EM, Aisen PS, Strittmatter SM.

JAMA Neurol. 2019 Jul 22. doi: 10.1001/jamaneurol.2019.2050. [Epub ahead of print]

5.

Predicting the course of Alzheimer's progression.

Iddi S, Li D, Aisen PS, Rafii MS, Thompson WK, Donohue MC; Alzheimer’s Disease Neuroimaging Initiative.

Brain Inform. 2019 Jun 28;6(1):6. doi: 10.1186/s40708-019-0099-0.

6.

Advancing Alzheimer's Disease Treatment: Lessons from CTAD 2018.

Vellas B, Bain LJ, Touchon J, Aisen PS.

J Prev Alzheimers Dis. 2019;6(3):198-203. doi: 10.14283/jpad.2019.11.

PMID:
31062835
7.

Editorial: Failure After Failure. What Next in AD Drug Development?

Aisen PS.

J Prev Alzheimers Dis. 2019;6(3):150. doi: 10.14283/jpad.2019.23. No abstract available.

PMID:
31062821
8.

Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease.

Egan MF, Kost J, Voss T, Mukai Y, Aisen PS, Cummings JL, Tariot PN, Vellas B, van Dyck CH, Boada M, Zhang Y, Li W, Furtek C, Mahoney E, Harper Mozley L, Mo Y, Sur C, Michelson D.

N Engl J Med. 2019 Apr 11;380(15):1408-1420. doi: 10.1056/NEJMoa1812840.

PMID:
30970186
9.

A randomized clinical trial to evaluate home-based assessment of people over 75 years old.

Sano M, Zhu CW, Kaye J, Mundt JC, Hayes TL, Ferris S, Thomas RG, Sun CK, Jiang Y, Donohue MC, Schneider LS, Egelko S, Aisen PS, Feldman HH; Alzheimer Disease Cooperative Study Investigators.

Alzheimers Dement. 2019 May;15(5):615-624. doi: 10.1016/j.jalz.2019.01.007. Epub 2019 Mar 11.

PMID:
30872114
10.

Unsuccessful trials of therapies for Alzheimer's disease.

Schott JM, Aisen PS, Cummings JL, Howard RJ, Fox NC.

Lancet. 2019 Jan 5;393(10166):29. doi: 10.1016/S0140-6736(18)31896-8. No abstract available.

PMID:
30614456
11.

Alzheimer's Disease Clinical Trials: Moving Toward Successful Prevention.

Rafii MS, Aisen PS.

CNS Drugs. 2019 Feb;33(2):99-106. doi: 10.1007/s40263-018-0598-1.

PMID:
30560544
12.

Automated and manual hippocampal segmentation techniques: Comparison of results, reproducibility and clinical applicability.

Hurtz S, Chow N, Watson AE, Somme JH, Goukasian N, Hwang KS, Morra J, Elashoff D, Gao S, Petersen RC, Aisen PS, Thompson PM, Apostolova LG.

Neuroimage Clin. 2019;21:101574. doi: 10.1016/j.nicl.2018.10.012. Epub 2018 Oct 14.

13.

Bayesian latent time joint mixed-effects model of progression in the Alzheimer's Disease Neuroimaging Initiative.

Li D, Iddi S, Thompson WK, Rafii MS, Aisen PS, Donohue MC.

Alzheimers Dement (Amst). 2018 Aug 29;10:657-668. doi: 10.1016/j.dadm.2018.07.008. eCollection 2018.

14.

Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.

Veitch DP, Weiner MW, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR Jr, Jagust W, Morris JC, Petersen RC, Saykin AJ, Shaw LM, Toga AW, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2019 Jan;15(1):106-152. doi: 10.1016/j.jalz.2018.08.005. Epub 2018 Oct 13. Review.

PMID:
30321505
15.

Participant satisfaction with dementia prevention research: Results from Home-Based Assessment trial.

Sano M, Egelko S, Zhu CW, Li C, Donohue MC, Ferris S, Kaye J, Mundt JC, Sun CK, Aisen PS, Feldman HH.

Alzheimers Dement. 2018 Nov;14(11):1397-1405. doi: 10.1016/j.jalz.2018.05.016. Epub 2018 Oct 5.

PMID:
30297140
16.

Defining the Optimal Target Population for Trials of Polyunsaturated Fatty Acid Supplementation Using the Erythrocyte Omega-3 Index: A Step Towards Personalized Prevention of Cognitive Decline?

Coley N, Raman R, Donohue MC, Aisen PS, Vellas B, Andrieu S.

J Nutr Health Aging. 2018;22(8):982-998. doi: /10.1007/s12603-018-1052-2.

PMID:
30272103
17.

Estimating the Evolution of Disease in the Parkinson's Progression Markers Initiative.

Iddi S, Li D, Aisen PS, Rafii MS, Litvan I, Thompson WK, Donohue MC.

Neurodegener Dis. 2018;18(4):173-190. doi: 10.1159/000488780. Epub 2018 Aug 8.

18.

What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force.

Aisen PS, Siemers E, Michelson D, Salloway S, Sampaio C, Carrillo MC, Sperling R, Doody R, Scheltens P, Bateman R, Weiner M, Vellas B.

J Prev Alzheimers Dis. 2018;5(3):171-174. doi: 10.14283/jpad.2018.23.

PMID:
29972209
19.

Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials.

Iwatsubo T, Iwata A, Suzuki K, Ihara R, Arai H, Ishii K, Senda M, Ito K, Ikeuchi T, Kuwano R, Matsuda H; Japanese Alzheimer's Disease Neuroimaging Initiative, Sun CK, Beckett LA, Petersen RC, Weiner MW, Aisen PS, Donohue MC; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2018 Aug;14(8):1077-1087. doi: 10.1016/j.jalz.2018.03.009. Epub 2018 May 9.

20.

Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.

Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, Sur C, Mukai Y, Voss T, Furtek C, Mahoney E, Harper Mozley L, Vandenberghe R, Mo Y, Michelson D.

N Engl J Med. 2018 May 3;378(18):1691-1703. doi: 10.1056/NEJMoa1706441.

Supplemental Content

Loading ...
Support Center